San Francisco - Based on clinical efficacy data, botulinum toxin A (Botox) should become the treatment of choice for suppressing axillary hyperhidrosis, according to Nicholas J. Lowe, M.D.
Federal Trade Commission Votes to Ban Noncompete Clauses Between Employers and Workers
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment
US Central and European Commands Should Revisit Disallowance of Systemic Treatments for Deployed Individuals With Psoriasis, Eczema, Paper Argues
ReV Up Your Vitiligo Treatment Strategies
ASLAN Announces Positive Phase 2 Results of Eblasakimab in Dupilumab-Treated Patients With AD
Jessner’s Lymphocytic Infiltration of the Skin Mimicking Rosacea: A Rare Case Presentation